Processa Pharmaceuticals, Inc. (PCSA)
- Previous Close
2.2600 - Open
2.3000 - Bid 1.6300 x 200
- Ask 2.8000 x 200
- Day's Range
2.1500 - 2.3000 - 52 Week Range
1.4000 - 18.0000 - Volume
88,569 - Avg. Volume
1,518,396 - Market Cap (intraday)
6.202M - Beta (5Y Monthly) 0.52
- PE Ratio (TTM)
-- - EPS (TTM)
-8.4800 - Earnings Date May 13, 2024 - May 17, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
44.00
Processa Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops chemotherapy drugs to improve the safety and efficacy of cancer treatment. Its drugs are modifications of existing FDA-approved oncology drugs resulting in an alteration of the metabolism and/or distribution of drugs while maintaining the existing mechanisms of killing the cancer cells. The company's pipeline includes three chemotherapy drugs comprising Gemcitabine, PCS3117 that has completed Phase 2a clinical trials to treat pancreatic, biliary tract, lung, ovarian, breast, and other cancers; Capecitabine, a combination of PCS6422 and capecitabine that has completed Phase 1b clinical trials to treat metastatic colorectal, gastrointestinal, breast, pancreatic, and other cancers; and Irinotecan, PCS11T that is in pre-clinical studies to treat lung, colorectal, gastrointestinal, pancreatic, and other cancers. It also develops non-oncology drugs consisting of PCS12852 for treatment of gastroparesis; and PCS499 to treat patients with ulcerative and non-ulcerative necrobiosis lipoidica. The company has license agreements with Elion Oncology, Inc.; Ocuphire Pharma, Inc.; Aposense, Ltd.; Yuhan Corporation; and CoNCERT Pharmaceuticals, Inc. Processa Pharmaceuticals, Inc. was founded in 2011 and is based in Hanover, Maryland.
www.processapharmaceuticals.comRecent News: PCSA
Performance Overview: PCSA
Trailing total returns as of 5/3/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: PCSA
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: PCSA
Valuation Measures
Market Cap
6.20M
Enterprise Value
1.64M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
1.24
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
-0.14
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-99.41%
Return on Equity (ttm)
-178.52%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-11.12M
Diluted EPS (ttm)
-8.4800
Balance Sheet and Cash Flow
Total Cash (mrq)
4.71M
Total Debt/Equity (mrq)
3.02%
Levered Free Cash Flow (ttm)
-4.11M
Research Analysis: PCSA
Company Insights: PCSA
PCSA does not have Company Insights